Nasdaq IPOs

ADC Therapeutics, a Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult-to-treat cancers, raised $233 million by offering 12.2 million shares at $19, above the range of $16 to $18. The company had originally filed to sell 7.4 million shares before ups

Novus Capital Corp, a blank check company targeting the smart technology innovations market, raised $100 million by offering 10 million units at $10. Units consist of one share of common stock and one warrant exercisable at $11.50. The Indianapolis, IN-based SPAC originally filed

GigCapital3, the third blank check company led by semiconductor veteran Avi Katz, raised $200 million by offering 20 million units at $10. Anchor investor Cohen & Co indicated on $17 million of the IPO (9% of the deal). Units consist of one share of common stock and 3/4 of on

Calliditas Therapeutics, a Swedish biotech developing novel therapies for inflammatory kidney disease, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The company's stock currently trades on the Nasdaq Stockholm under the symbol "CALTX" an

Calliditas Therapeutics, a Swedish biotech developing novel therapies for inflammatory kidney disease, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The company's stock currently trades on the Nasdaq Stockholm under the symbol "CALTX" an

NuZee, which packages and sells single-serve coffee products, announced terms for its IPO on Thursday. In its latest filing, the company also disclosed financial results for the six months ended March 31, 2020. The Plano, TX-based company plans to raise $5 million by offering 555

Jaws Acquisition, a blank check company led by Starwood Capital founder Barry Sternlicht, raised $600 million by offering 60 million units at $10. The company originally planned to offer 40 million units before increasing its proposed unit offering to 50 million last week. Each u

Jaws Acquisition, a blank check company led by Starwood Capital founder Barry Sternlicht, raised $600 million by offering 60 million units at $10. The company originally planned to offer 40 million units before increasing its proposed unit offering to 50 million last week. Each u

ADC Therapeutics, a Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult cancers, increased the proposed share offering for its upcoming IPO on Thursday. The Épalinges, Switzerland-based company now plans to raise $175 million by offering 10.3 m

Legend Biotech, a clinical stage oncology biotech being spun-out of GenScript's cell therapy unit, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Legend's extensive pipeline contains lead candidate LCAR-B38M/JNJ-4528, a CAR-T therapy be

Dada Nexus, a leading on-demand retail and delivery platform in China, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. However, this is likely a placeholder for a deal we estimate could raise up to $500 million. Dada Nexus operat

Coro Global, which is developing a gold-focused payment application and financial security platform, filed on Tuesday with the SEC to raise up to $13 million in an initial public offering. The company is currently quoted on the OTC Pink under the symbol "CGLO" and last closed at

Lantern Pharma, a Phase 2 oncology biotech using AI to redevelop abandoned drugs for targeted groups, announced terms for its IPO on Tuesday. The Dallas, TX-based company plans to raise $25 million by offering 1.6 million shares at a price range of $15 to $17. At the midpoint of

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, filed on Monday with the SEC to raise up to $20 million in an initial public offering. Kiromic's pipeline consists of four early-stage product candidates targeting blood cancer

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, filed on Monday with the SEC to raise up to $20 million in an initial public offering. Kiromic's pipeline consists of four early-stage product candidates targeting blood cancer

Global Internet of People, an online peer-to-peer knowledge sharing and enterprise service platform in China, decreased the proposed share offering and increased the proposed price point for its upcoming IPO on Monday. In its latest filing, the company also disclosed financials f

Pliant Therapeutics, a Phase 2 biotech developing therapies for the treatment of fibrosis, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The company plans to raise an additional $10 million through a concurrent private placement to Novarti

ADC Therapeutics, a Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult cancers, announced terms for its IPO on Monday. The Épalinges, Switzerland-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16

Updated Monday, 5/11. Just one IPO is on the calendar for the week ahead, but that could quickly change. In the past month, five companies have launched and priced IPOs within one week. US grocer Albertsons (ACI) and Chinese crypto mining company Ebang International (EBON) are pr

There are currently no IPOs on the calendar for the week ahead, but that could quickly change. In the past month, five companies have launched and priced IPOs within one week. US grocer Albertsons (ACI), Chinese crypto mining company Ebang International (EBON), and Swiss oncology